Lonza (Basel, Switzerland), broke ground earlier this week on a new cell therapy manufacturing facility in Tuas Biomedical Park, Singapore, adjacent to Lonza’s large-scale mammalian manufacturing facility.
The construction project began in May of this year, and actual construction will begin in early 2010. The facility is expected to begin manufacturing therapies in the first two suites by mid-2011. The facility is designed to accommodate additional suites built to meet incremental customer demand. The total investment for the first phase will be approximately CHF 30 million Swiss Francs (about US $29 millions).
Lonza already has 12 cGMP-certified cell therapy manufacturing suites in the US and Europe.
